Do analysts prefer CDT or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CDT or ADXN more profitable?

CDT Equity's return on equity of -72.25% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Addex Therapeutics N/A -134.76% -106.00%

Does the media prefer CDT or ADXN?

In the previous week, Addex Therapeutics had 2 more articles in the media than CDT Equity. MarketBeat recorded 8 mentions for Addex Therapeutics and 6 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.14 beat Addex Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INM or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GLMD or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, GLMD or CDT?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$7.28 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is GLMD or CDT more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% CDT Equity N/A -72.25% -55.44%

Does the media favor GLMD or CDT?

In the previous week, CDT Equity had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for CDT Equity and 5 mentions for Galmed Pharmaceuticals. CDT Equity's average media sentiment score of 1.14 beat Galmed Pharmaceuticals' score of 0.53 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SBFM or CDT?

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 6,040.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate GRI or CDT?

GRI Bio currently has a consensus price target of $32.00, suggesting a potential upside of 1,532.65%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GRI or CDT?

GRI Bio is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$38.37 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is GRI or CDT more profitable?

CDT Equity's return on equity of -72.25% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% CDT Equity N/A -72.25% -55.44%

Does the media favor GRI or CDT?

In the previous week, CDT Equity had 3 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for CDT Equity and 3 mentions for GRI Bio. CDT Equity's average media sentiment score of 1.14 beat GRI Bio's score of 0.50 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CDT Equity (CDT) Competitors

$2.05 -0.44 (-17.67%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$2.05 +0.00 (+0.20%)

As of 06:37 AM Eastern

Compare

CDT vs. ADXN, INM, GLMD, SBFM, and GRI

Should you buy CDT Equity stock or one of its competitors? CDT Equity's main competitors and comparable companies include Addex Therapeutics (ADXN), InMed Pharmaceuticals (INM), Galmed Pharmaceuticals (GLMD), Sunshine Biopharma (SBFM), and GRI Bio (GRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CDT Equity compare to Addex Therapeutics?

CDT Equity (NASDAQ:CDT) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 7.3% of CDT Equity shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CDT Equity has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

CDT Equity's return on equity of -72.25% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Addex Therapeutics	N/A	-134.76%	-106.00%

Addex Therapeutics has higher revenue and earnings than CDT Equity. Addex Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Addex Therapeutics	$210K	22.84	-$8.12M	-$5.94	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Addex Therapeutics had 2 more articles in the media than CDT Equity. MarketBeat recorded 8 mentions for Addex Therapeutics and 6 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.14 beat Addex Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Addex Therapeutics beats CDT Equity on 6 of the 11 factors compared between the two stocks.

How does CDT Equity compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

In the previous week, CDT Equity had 5 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 6 mentions for CDT Equity and 1 mentions for InMed Pharmaceuticals. CDT Equity's average media sentiment score of 1.14 beat InMed Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
CDT Equity	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InMed Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

CDT Equity has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. CDT Equity's return on equity of -72.25% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
CDT Equity	N/A	-72.25%	-55.44%

InMed Pharmaceuticals has higher revenue and earnings than CDT Equity. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.96	-$8.16M	-$2.89	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

Summary

CDT Equity beats InMed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does CDT Equity compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Galmed Pharmaceuticals' return on equity of -35.32% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
CDT Equity	N/A	-72.25%	-55.44%

Galmed Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, CDT Equity had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for CDT Equity and 5 mentions for Galmed Pharmaceuticals. CDT Equity's average media sentiment score of 1.14 beat Galmed Pharmaceuticals' score of 0.53 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Galmed Pharmaceuticals beats CDT Equity on 6 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, CDT Equity had 4 more articles in the media than Sunshine Biopharma. MarketBeat recorded 6 mentions for CDT Equity and 2 mentions for Sunshine Biopharma. CDT Equity's average media sentiment score of 1.14 beat Sunshine Biopharma's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
CDT Equity	Positive

Sunshine Biopharma has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than CDT Equity. Sunshine Biopharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.12	-$5.97M	-$10.15	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by insiders. Comparatively, 7.3% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CDT Equity has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
CDT Equity	N/A	-72.25%	-55.44%

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 6,040.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sunshine Biopharma beats CDT Equity on 9 of the 15 factors compared between the two stocks.

How does CDT Equity compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

GRI Bio is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

In the previous week, CDT Equity had 3 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for CDT Equity and 3 mentions for GRI Bio. CDT Equity's average media sentiment score of 1.14 beat GRI Bio's score of 0.50 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRI Bio has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

GRI Bio currently has a consensus price target of $32.00, suggesting a potential upside of 1,532.65%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 7.3% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CDT Equity's return on equity of -72.25% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
CDT Equity	N/A	-72.25%	-55.44%

Summary

GRI Bio beats CDT Equity on 7 of the 13 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.96M	$12.52B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	0.00	778.15	271.01	24.15
Price / Sales	N/A	753.37	630.63	102.20
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.02	12.01	13.02	6.25
Net Income	-$39.22M	$2.80B	$3.46B	$347.86M
7 Day Performance	-31.89%	2.87%	1.53%	0.98%
1 Month Performance	-33.01%	6.54%	8.82%	5.24%
1 Year Performance	-99.93%	8.04%	26.07%	17.04%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	1.2845 of 5 stars	$2.05 -17.7%	N/A	-99.9%	$1.96M	N/A	N/A	3	News Coverage Positive News Short Interest Decrease High Trading Volume
ADXN Addex Therapeutics	0.226 of 5 stars	$3.90 -3.7%	N/A	-53.2%	$4.80M	$210K	N/A	30	News Coverage Short Interest Increase
INM InMed Pharmaceuticals	1.3377 of 5 stars	$1.44 +0.7%	N/A	-35.4%	$4.77M	$4.94M	N/A	10
GLMD Galmed Pharmaceuticals	1.4215 of 5 stars	$4.31 +6.4%	N/A	-61.8%	$4.48M	N/A	N/A	20	Short Interest Decrease
SBFM Sunshine Biopharma	2.8826 of 5 stars	$1.14 -1.7%	$70.00 +6,040.4%	-91.9%	$4.42M	$35.35M	N/A	3	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. ADXN, INM, GLMD, SBFM, and GRI

How does CDT Equity compare to Addex Therapeutics?

Summary

How does CDT Equity compare to InMed Pharmaceuticals?

Summary

How does CDT Equity compare to Galmed Pharmaceuticals?

Summary

How does CDT Equity compare to Sunshine Biopharma?

Summary

How does CDT Equity compare to GRI Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. ADXN, INM, GLMD, SBFM, and GRI

How does CDT Equity compare to Addex Therapeutics?

Do insiders & institutionals hold more shares of CDT or ADXN?

Which has more volatility & risk, CDT or ADXN?

Is CDT or ADXN more profitable?

Which has stronger valuation & earnings, CDT or ADXN?

Do analysts prefer CDT or ADXN?

Does the media prefer CDT or ADXN?

Summary

How does CDT Equity compare to InMed Pharmaceuticals?

Does the media favor INM or CDT?

Do analysts prefer INM or CDT?

Do institutionals & insiders hold more shares of INM or CDT?

Which has more volatility and risk, INM or CDT?

Is INM or CDT more profitable?

Which has higher earnings & valuation, INM or CDT?

Summary

How does CDT Equity compare to Galmed Pharmaceuticals?

Is GLMD or CDT more profitable?

Which has more volatility & risk, GLMD or CDT?

Does the media favor GLMD or CDT?

Do institutionals and insiders hold more shares of GLMD or CDT?

Which has preferable valuation & earnings, GLMD or CDT?

Do analysts prefer GLMD or CDT?

Summary

How does CDT Equity compare to Sunshine Biopharma?

Does the media refer more to SBFM or CDT?

Which has more risk & volatility, SBFM or CDT?

Which has better earnings & valuation, SBFM or CDT?

Do insiders and institutionals hold more shares of SBFM or CDT?

Is SBFM or CDT more profitable?

Do analysts recommend SBFM or CDT?

Summary

How does CDT Equity compare to GRI Bio?

Which has better valuation and earnings, GRI or CDT?

Does the media favor GRI or CDT?

Which has more volatility and risk, GRI or CDT?

Do analysts rate GRI or CDT?

Do insiders & institutionals hold more shares of GRI or CDT?

Is GRI or CDT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools